周五，Cidara Therapeutics, Inc.（股票代码：CDTX）股价盘中大涨105.58%，引发市场广泛关注。这一显著涨幅源于制药巨头默克公司（Merck）宣布将以约92亿美元收购Cidara Therapeutics。
根据双方达成的协议，默克将通过其子公司以每股221.50美元的现金价格收购Cidara的所有流通股，较Cidara最后收盘价溢价108.9%。这一高溢价反映了市场对Cidara在抗感染药物研发领域实力的高度认可，尤其是其主打产品CD388的巨大潜力。
Cidara的明星产品CD388是一种长效抗病毒药物，旨在为流感高危人群提供全年保护。上个月，CD388获得了美国食品和药物管理局（FDA）授予的"突破性疗法"称号，这将加快其审批进程。对默克而言，收购Cidara不仅可以增强其在呼吸系统疾病领域的竞争力，还有望在其重磅药物Keytruda专利到期前为公司带来新的增长点。该交易预计将于2026年第一季度完成，受监管机构批准等常规交割条件的约束。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.